/ RAPP
Why Did Rapport Therapeutics, Inc Shares Skyrocket in Premarket?
Rapport Therapeutics shares surged in premarket trading after announcing positive Phase 2a trial results for RAP-219, showing 77.8% reduction in clinical ...
September 08, 2025